Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of milvexian versus apixaban for stroke and systemic embolism prevention in adults with atrial fibrillation
CTR20240725Phase 3Active
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of milvexian in Atrial fibrillation (AFib) and atrial flutter (AFL) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Time to first stroke or non-CNS systemic embolism. Started Mar 2024; status: active.
02
Drugs
milvexian
03
Conditions
Atrial fibrillation (AFib)atrial flutter (AFL)
Beyond the preview
Go deeper on CTR20240725.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240725.